ReviewThe Journal of physiology2025
The impact of androgens on cardiovascular control mechanisms in polycystic ovary syndrome: Recent advances and translational approaches.
Review in The Journal of physiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Early in, early out: reproductive lifespan timing and cardiometabolic risk in women.Journal of endocrinological investigation · 2026Review
- Testosterone: Vital to female physiology.Women's health (London, England)Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Polycystic ovary syndrome (PCOS) is the most common endocrinopathy in premenopausal females. The condition is associated with an increased prevalence of cardiovascular risk factors, including hypertension. Observational studies report that some blood pressure control mechanisms are altered in PCOS compared to controls (sympathetic nervous system activity, endothelial and vasodilator function, renin angiotensin aldosterone system activation), and that these impairments correlate with androgen hormone levels, which are chronically elevated in the condition. As such, hyperandrogenism is the proposed locus of origin for the link between PCOS and cardiovascular dysfunction, yet the underlying mechanisms remain poorly understood. Preclinical work has provided some insight into how androgens modulate blood pressure control in PCOS. However there are marked discrepancies between the effects of androgens in cellular and tissue studies versus in vivo animal and human PCOS studies. This may be related to the heterogeneity of the preclinical models and samples used in this research and whether preclinical work is modelling hyperandrogenism in physiologically relevant terms for PCOS. This review collates preclinical and clinical evidence to summarise what is known and what remains unknown about cardiovascular control mechanisms in PCOS. We examine aspects of blood pressure regulation that are altered in other hypertensive cohorts, presenting current evidence for a mechanistic role of androgens on these systems, while acknowledging the diverse experimental models and participant cohorts from which the results are derived.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.